In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Aeterna Zentaris (NASDAQ: AEZS), with a price target of $3. The company’s shares closed yesterday at $1.79.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 4.3% and a 35.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.
Aeterna Zentaris has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.
See today’s analyst top recommended stocks >>
Based on Aeterna Zentaris’ latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $14.42 million. In comparison, last year the company had a GAAP net loss of $4.13 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. It operates through biopharmaceutical segment. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Charleston, SC.
Read More on AEZS:
